BeiGene, Ltd. (NASDAQ:BGNE) Short Interest Up 33.1% in November

BeiGene, Ltd. (NASDAQ:BGNE) was the target of a large increase in short interest during the month of November. As of November 30th, there was short interest totalling 1,330,000 shares, an increase of 33.1% from the November 15th total of 999,400 shares. Based on an average daily volume of 367,900 shares, the short-interest ratio is currently 3.6 days.

Insider Buying and Selling

In related news, Director Bros. Advisors Lp Baker sold 1,037,017 shares of the stock in a transaction dated Monday, December 9th. The shares were sold at an average price of $187.27, for a total value of $194,202,173.59. Following the completion of the transaction, the director now owns 791,493 shares in the company, valued at $148,222,894.11. This represents a 56.71 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, SVP Chan Henry Lee sold 1,202 shares of the business’s stock in a transaction dated Monday, September 30th. The stock was sold at an average price of $237.10, for a total transaction of $284,994.20. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 1,136,622 shares of company stock valued at $213,521,417. Insiders own 7.43% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the company. Driehaus Capital Management LLC acquired a new stake in shares of BeiGene in the second quarter valued at about $1,168,000. The Manufacturers Life Insurance Company increased its position in BeiGene by 8.4% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 50,262 shares of the company’s stock worth $7,171,000 after buying an additional 3,915 shares during the period. Connor Clark & Lunn Investment Management Ltd. increased its position in BeiGene by 160.0% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 225,854 shares of the company’s stock worth $50,706,000 after buying an additional 138,978 shares during the period. Van ECK Associates Corp boosted its position in shares of BeiGene by 8.9% in the second quarter. Van ECK Associates Corp now owns 95,577 shares of the company’s stock valued at $13,636,000 after acquiring an additional 7,816 shares during the period. Finally, Barings LLC boosted its position in shares of BeiGene by 66.4% in the second quarter. Barings LLC now owns 51,763 shares of the company’s stock valued at $7,385,000 after acquiring an additional 20,663 shares during the period. Institutional investors own 48.55% of the company’s stock.

BeiGene Stock Down 0.5 %

Shares of BeiGene stock traded down $0.92 during midday trading on Friday, reaching $179.35. 368,615 shares of the company’s stock traded hands, compared to its average volume of 281,770. The company has a market cap of $17.47 billion, a price-to-earnings ratio of -21.77 and a beta of 0.57. BeiGene has a 52 week low of $126.97 and a 52 week high of $248.16. The company’s 50 day simple moving average is $207.23 and its 200 day simple moving average is $186.66. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.72 and a current ratio of 1.93.

BeiGene (NASDAQ:BGNE) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($1.15) EPS for the quarter, missing analysts’ consensus estimates of ($1.11) by ($0.04). The company had revenue of $1 billion for the quarter, compared to analyst estimates of $983.26 million. BeiGene had a negative net margin of 25.94% and a negative return on equity of 25.12%. The business’s revenue was up 28.2% on a year-over-year basis. During the same period in the prior year, the company posted $2.01 EPS. Equities analysts expect that BeiGene will post -5.64 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms recently issued reports on BGNE. JPMorgan Chase & Co. lifted their target price on BeiGene from $200.00 to $235.00 and gave the stock an “overweight” rating in a report on Tuesday, October 22nd. TD Cowen increased their target price on BeiGene from $254.00 to $260.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. Morgan Stanley reiterated an “overweight” rating and set a $300.00 price target on shares of BeiGene in a report on Tuesday, December 3rd. StockNews.com downgraded BeiGene from a “buy” rating to a “hold” rating in a research note on Thursday, November 21st. Finally, JMP Securities assumed coverage on BeiGene in a report on Wednesday, September 18th. They issued a “market outperform” rating and a $288.00 target price on the stock. Three analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, BeiGene presently has a consensus rating of “Moderate Buy” and a consensus price target of $253.69.

BeiGene Company Profile

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.